Moreover, a randomized clinical trial in patients with advanced pancreatic carcinoma demonstrates that combination of the anti-IGF-IR mAb MK-0646 with gemcitabine is tolerable and associated with improvement in overall survival but not progression-free survival as compared with gemcitabine plus erlotinib [151]
doi: 10.3390/ijms18030484 229 DengSLeongHCDattaAGopalVKumarAPYapCT
Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, et al
In NFP's recent annual employer survey, 51% of employers cited GLP-1s as the top driver of rising prescription drug costs
Archives of Facial Plastic Surgery, 2005, 7 1
32 Modernas therapy development process allows for rapid deployment of vaccines with projected 60-day timelines prior to in-human clinical trials